Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Incidence of Tardive Dyskinesia in the Study of Pharmacotherapy for Psychotic Depression</title><author><name sortKey="Blumberger, Daniel M" sort="Blumberger, Daniel M" uniqKey="Blumberger D" first="Daniel M." last="Blumberger">Daniel M. Blumberger</name><affiliation><nlm:aff id="A1">Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</nlm:aff></affiliation></author><author><name sortKey="Mulsant, Benoit H" sort="Mulsant, Benoit H" uniqKey="Mulsant B" first="Benoit H." last="Mulsant">Benoit H. Mulsant</name><affiliation><nlm:aff id="A1">Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA</nlm:aff></affiliation></author><author><name sortKey="Kanellopoulos, Dora" sort="Kanellopoulos, Dora" uniqKey="Kanellopoulos D" first="Dora" last="Kanellopoulos">Dora Kanellopoulos</name><affiliation><nlm:aff id="A3">Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital–Westchester Division, New York, NY</nlm:aff></affiliation></author><author><name sortKey="Whyte, Ellen M" sort="Whyte, Ellen M" uniqKey="Whyte E" first="Ellen M." last="Whyte">Ellen M. Whyte</name><affiliation><nlm:aff id="A2">Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA</nlm:aff></affiliation></author><author><name sortKey="Rothschild, Anthony J" sort="Rothschild, Anthony J" uniqKey="Rothschild A" first="Anthony J." last="Rothschild">Anthony J. Rothschild</name><affiliation><nlm:aff id="A4">University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA</nlm:aff></affiliation></author><author><name sortKey="Flint, Alastair J" sort="Flint, Alastair J" uniqKey="Flint A" first="Alastair J." last="Flint">Alastair J. Flint</name><affiliation><nlm:aff id="A5">Departments of Psychiatry, University Health Network and University of Toronto, Toronto, Ontario, Canada</nlm:aff></affiliation></author><author><name sortKey="Meyers, Barnett S" sort="Meyers, Barnett S" uniqKey="Meyers B" first="Barnett S." last="Meyers">Barnett S. Meyers</name><affiliation><nlm:aff id="A3">Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital–Westchester Division, New York, NY</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23609383</idno><idno type="pmc">4061483</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061483</idno><idno type="RBID">PMC:4061483</idno><idno type="doi">10.1097/JCP.0b013e31828bf059</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000816</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000816</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The Incidence of Tardive Dyskinesia in the Study of Pharmacotherapy for Psychotic Depression</title><author><name sortKey="Blumberger, Daniel M" sort="Blumberger, Daniel M" uniqKey="Blumberger D" first="Daniel M." last="Blumberger">Daniel M. Blumberger</name><affiliation><nlm:aff id="A1">Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</nlm:aff></affiliation></author><author><name sortKey="Mulsant, Benoit H" sort="Mulsant, Benoit H" uniqKey="Mulsant B" first="Benoit H." last="Mulsant">Benoit H. Mulsant</name><affiliation><nlm:aff id="A1">Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA</nlm:aff></affiliation></author><author><name sortKey="Kanellopoulos, Dora" sort="Kanellopoulos, Dora" uniqKey="Kanellopoulos D" first="Dora" last="Kanellopoulos">Dora Kanellopoulos</name><affiliation><nlm:aff id="A3">Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital–Westchester Division, New York, NY</nlm:aff></affiliation></author><author><name sortKey="Whyte, Ellen M" sort="Whyte, Ellen M" uniqKey="Whyte E" first="Ellen M." last="Whyte">Ellen M. Whyte</name><affiliation><nlm:aff id="A2">Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA</nlm:aff></affiliation></author><author><name sortKey="Rothschild, Anthony J" sort="Rothschild, Anthony J" uniqKey="Rothschild A" first="Anthony J." last="Rothschild">Anthony J. Rothschild</name><affiliation><nlm:aff id="A4">University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA</nlm:aff></affiliation></author><author><name sortKey="Flint, Alastair J" sort="Flint, Alastair J" uniqKey="Flint A" first="Alastair J." last="Flint">Alastair J. Flint</name><affiliation><nlm:aff id="A5">Departments of Psychiatry, University Health Network and University of Toronto, Toronto, Ontario, Canada</nlm:aff></affiliation></author><author><name sortKey="Meyers, Barnett S" sort="Meyers, Barnett S" uniqKey="Meyers B" first="Barnett S." last="Meyers">Barnett S. Meyers</name><affiliation><nlm:aff id="A3">Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital–Westchester Division, New York, NY</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of clinical psychopharmacology</title><idno type="ISSN">0271-0749</idno><idno type="eISSN">1533-712X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Tardive dyskinesia (TD) is a debilitating adverse effect associated with antipsychotic treatment. Older age and the presence of mood disorder have been identified as risk factors for the development of TD. Thus, we assessed the incidence of TD in younger and older patients with major depressive disorder with psychotic features who participated in a 12-week clinical trial comparing olanzapine plus sertraline versus olanzapine plus placebo. All subjects (n = 259) were assessed with the Abnormal Involuntary Movement Scale at baseline and after 4, 8, and 12 weeks of treatment (or at termination). We used 7 different published criteria to estimate the prevalence of TD at baseline and the incidence over the duration of the trial. We compared the incidence of TD in subjects 60 years or older and those younger than 60 years. The overall prevalence and incidence of TD varied almost 10-fold, depending on the criteria (prevalence range, 1.2%–8.9%; incidence range, 0.0%–5.9%). Tardive dyskinesia was observed as a clinical adverse event in only 1 subject (0.4%). Whereas older subjects had a higher prevalence of TD at baseline, the incidence in younger and older subjects did not differ significantly. The incidence of TD was relatively low in both younger and older patients with major depressive disorder with psychotic features treated acutely with olanzapine. However, the estimate of the risk of TD varies widely, depending on the criteria used to define TD.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8109496</journal-id><journal-id journal-id-type="pubmed-jr-id">4660</journal-id><journal-id journal-id-type="nlm-ta">J Clin Psychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Psychopharmacol</journal-id><journal-title-group><journal-title>Journal of clinical psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0271-0749</issn><issn pub-type="epub">1533-712X</issn></journal-meta><article-meta><article-id pub-id-type="pmid">23609383</article-id><article-id pub-id-type="pmc">4061483</article-id><article-id pub-id-type="doi">10.1097/JCP.0b013e31828bf059</article-id><article-id pub-id-type="manuscript">NIHMS577664</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Incidence of Tardive Dyskinesia in the Study of Pharmacotherapy for Psychotic Depression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Blumberger</surname><given-names>Daniel M.</given-names></name><degrees>MD, MSc, FRCPC</degrees><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Mulsant</surname><given-names>Benoit H.</given-names></name><degrees>MD, MS, FRCPC</degrees><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A2">†</xref></contrib><contrib contrib-type="author"><name><surname>Kanellopoulos</surname><given-names>Dora</given-names></name><degrees>MA</degrees><xref ref-type="aff" rid="A3">‡</xref></contrib><contrib contrib-type="author"><name><surname>Whyte</surname><given-names>Ellen M.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">†</xref></contrib><contrib contrib-type="author"><name><surname>Rothschild</surname><given-names>Anthony J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">§</xref></contrib><contrib contrib-type="author"><name><surname>Flint</surname><given-names>Alastair J.</given-names></name><degrees>MB, FRCPC, FRANZCP</degrees><xref ref-type="aff" rid="A5">‖</xref></contrib><contrib contrib-type="author"><name><surname>Meyers</surname><given-names>Barnett S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A3">‡</xref></contrib></contrib-group><aff id="A1"><label>*</label>Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</aff><aff id="A2"><label>†</label>Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA</aff><aff id="A3"><label>‡</label>Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital–Westchester Division, New York, NY</aff><aff id="A4"><label>§</label>University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA</aff><aff id="A5"><label>‖</label>Departments of Psychiatry, University Health Network and University of Toronto, Toronto, Ontario, Canada</aff><author-notes><corresp id="cor1">Reprints: Benoit H. Mulsant, MD, MS, FRCPC, Centre for Addiction and Mental Health, 1001 Queen St West, Toronto, Ontario, Canada M6J 1H4 (<email>benoit_mulsant@camh.net</email>)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>1</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>6</month><year>2014</year></pub-date><volume>33</volume><issue>3</issue><fpage>391</fpage><lpage>397</lpage><pmc-comment>elocation-id from pubmed: 10.1097/JCP.0b013e31828bf059</pmc-comment>
<permissions><copyright-statement>Copyright © 2013 by Lippincott Williams & Wilkins</copyright-statement><copyright-year>2013</copyright-year></permissions><abstract><p id="P1">Tardive dyskinesia (TD) is a debilitating adverse effect associated with antipsychotic treatment. Older age and the presence of mood disorder have been identified as risk factors for the development of TD. Thus, we assessed the incidence of TD in younger and older patients with major depressive disorder with psychotic features who participated in a 12-week clinical trial comparing olanzapine plus sertraline versus olanzapine plus placebo. All subjects (n = 259) were assessed with the Abnormal Involuntary Movement Scale at baseline and after 4, 8, and 12 weeks of treatment (or at termination). We used 7 different published criteria to estimate the prevalence of TD at baseline and the incidence over the duration of the trial. We compared the incidence of TD in subjects 60 years or older and those younger than 60 years. The overall prevalence and incidence of TD varied almost 10-fold, depending on the criteria (prevalence range, 1.2%–8.9%; incidence range, 0.0%–5.9%). Tardive dyskinesia was observed as a clinical adverse event in only 1 subject (0.4%). Whereas older subjects had a higher prevalence of TD at baseline, the incidence in younger and older subjects did not differ significantly. The incidence of TD was relatively low in both younger and older patients with major depressive disorder with psychotic features treated acutely with olanzapine. However, the estimate of the risk of TD varies widely, depending on the criteria used to define TD.</p></abstract><kwd-group><kwd>psychotic depression</kwd><kwd>pharmacotherapy</kwd><kwd>tardive dyskinesia</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000816 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000816 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.29. |  |